Kapitalo Investimentos Ltda Has $464,000 Stock Position in Exelixis, Inc. (NASDAQ:EXEL)

Kapitalo Investimentos Ltda cut its position in Exelixis, Inc. (NASDAQ:EXEL) by 30.7% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 13,946 shares of the biotechnology company’s stock after selling 6,188 shares during the quarter. Exelixis accounts for 0.3% of Kapitalo Investimentos Ltda’s portfolio, making the stock its 21st biggest holding. Kapitalo Investimentos Ltda’s holdings in Exelixis were worth $464,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in EXEL. Invesco Ltd. grew its stake in Exelixis by 308.1% in the fourth quarter. Invesco Ltd. now owns 3,975,241 shares of the biotechnology company’s stock valued at $132,376,000 after acquiring an additional 3,001,204 shares during the period. Norges Bank acquired a new stake in Exelixis in the 4th quarter valued at $94,867,000. Arrowstreet Capital Limited Partnership increased its stake in Exelixis by 104.4% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 3,159,395 shares of the biotechnology company’s stock valued at $105,208,000 after purchasing an additional 1,613,482 shares in the last quarter. AQR Capital Management LLC raised its holdings in Exelixis by 25.7% during the fourth quarter. AQR Capital Management LLC now owns 3,967,005 shares of the biotechnology company’s stock worth $132,101,000 after buying an additional 810,857 shares during the last quarter. Finally, Fuller & Thaler Asset Management Inc. lifted its stake in shares of Exelixis by 10.2% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 7,630,940 shares of the biotechnology company’s stock valued at $254,110,000 after buying an additional 708,312 shares in the last quarter. 85.27% of the stock is owned by institutional investors.

Insider Activity

In related news, EVP Patrick J. Haley sold 52,636 shares of Exelixis stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $36.98, for a total value of $1,946,479.28. Following the completion of the transaction, the executive vice president now directly owns 303,310 shares in the company, valued at approximately $11,216,403.80. The trade was a 14.79 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bob Oliver sold 18,647 shares of the business’s stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $37.25, for a total transaction of $694,600.75. Following the sale, the director now directly owns 33,514 shares in the company, valued at $1,248,396.50. The trade was a 35.75 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 140,343 shares of company stock valued at $5,177,234 over the last quarter. Company insiders own 2.85% of the company’s stock.

Exelixis Price Performance

Shares of EXEL opened at $38.55 on Wednesday. Exelixis, Inc. has a 1 year low of $20.14 and a 1 year high of $40.02. The stock’s fifty day moving average price is $36.82 and its two-hundred day moving average price is $34.84. The firm has a market cap of $10.62 billion, a PE ratio of 21.78, a PEG ratio of 1.13 and a beta of 0.57.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. Sell-side analysts anticipate that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

EXEL has been the subject of several recent research reports. Stephens reissued an “equal weight” rating and set a $29.00 target price on shares of Exelixis in a research report on Wednesday, February 12th. Guggenheim reissued a “buy” rating and issued a $42.00 price objective on shares of Exelixis in a research note on Wednesday, February 12th. Stifel Nicolaus lifted their target price on Exelixis from $30.00 to $36.00 and gave the company a “hold” rating in a research report on Wednesday, February 12th. JMP Securities reissued a “market outperform” rating and issued a $41.00 price target on shares of Exelixis in a research report on Thursday, April 17th. Finally, Royal Bank of Canada raised their price objective on Exelixis from $38.00 to $40.00 and gave the company an “outperform” rating in a research note on Thursday, March 13th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.59.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.